Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kite trial of subcutaneous ketamine for bipolar depression
ACTRN12624000789561Phase 3Recruiting
- Sponsor
- University of Melbourne
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ketamine and midazolam in bipolar disorder (BD) (4 arms), sponsored by University of Melbourne. Primary endpoint: Effect of low-dose subcutaneous ketamine versus midazolam on depression symptoms at Day 19. Started Oct 2024; status: recruiting.
02
Drugs
ketaminemidazolam
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12624000789561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000789561.